TARS Q4 2021 Earnings — Tarsus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

TARSTarsus Pharmaceuticals, Inc.

$3B

Q4 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$338,000

Gross Profit

$362,000107.1% margin

Operating Income

-$14M-4274.6% margin

Net Income

-$15M-4393.8% margin

EPS (Diluted)

$-0.72

QoQ Revenue Growth

-72.7%

Cash Flow

Operating Cash Flow

-$12M

Free Cash Flow

-$12M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$179M

Total Liabilities

$12M

Stockholders' Equity

$167M

Cash & Equivalents

$171M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$338,000	$0	—
Gross Profit	$362,000	$0	—
Operating Income	-$14M	-$11M	-25.9%
Net Income	-$15M	-$11M	-29.5%